Dr Daniel Patterson : Medical oncology

Home
Dr Daniel Patterson

Bupa Platinum consultant
Fee assured
Verified account
Open Referral network

Overview

Offers

Face-to-face consultations
Video and telephone consultations
Home chemotherapy

About me

Experienced specialist in the systemic treatment of lung, gastrointestinal malignancies and carcinoma unknown primary. Particular interest in immunotherapies and molecular targeted therapies. Underwent training in London and obtained CCT in medical oncology in 2009. My aim is to always provide patients a balanced and tailored approach to their situation, and to explore all options available.

Areas of interest

Lung cancer; mesothelioma; oesophageal/gastric cancer; pancreatic cancer; small bowel cancer; cholangiocarcinoma; colorectal cancer; neuroendocrine tumours; cancer of unknown primary (CUP).

Medical secretaries

Ms Alison Hammond
West Suffolk Hospital Hardwick Lane BURY ST EDMUNDS IP33 2QZ
01284 713195
alison.hammond@wsh.nhs.uk

About me

Current NHS consultant posts held

Consultant Medical Oncologist West Suffolk Hospital

Research interests

Use of targeted therapies in lung & GI cancer
Phase II/III studies
Cancer unknown primary

Personal interests

Football, cricket, tennis
Reading
Music

Awards received

ASCO merit award 2008

Publications

Lightowlers S & Patterson D. Mismanagment of malignant hypercalcaemia (2013). Clin Med February 1, 2013 vol. 13 no. 1 118
Patterson D.M, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ (2012): Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25.
.
Patterson D. M, Aries J, Hyare H, Holder D, Rees, J and SM Lee (2011). Non-convulsive status epilepticus and leucoencephalopathy following high-dose methotrexate. J Clin Oncol. 2011 Jun 1;29(16):e459-61

Patterson D. M. and S. M. Lee (2010). Glucarpidase following high-dose methotrexate: update on development. Expert Opinion on Biological Therapy 10(1): 105-111

Whelan J, Patterson D. M, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M (2010). The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 54(3):350-4

Patterson, D. M., A. R. Padhani, et al. (2008). "Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy." Nat Clin Pract Oncol 5(4): 220-33.

Patterson, D. M., N. Murugaesu, et al. (2008). "A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites." International Journal of Gynecological Cancer 18(1): 43-50.

Patterson, D. M. and G. J. Rustin (2007). "Vascular Damaging Agents." Clin Oncol (R Coll Radiol) 19(6): 443-56.

My qualifications & training

My private practice

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (1-5)

Report this page Print page

Finder

Note: